The RANKL pathway and denosumab

Rheumatic Disease Clinics of North America

Volumn 37, Issue 3, 2011, Pages 433-452

  Dore, Robin K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Denosumab; FREEDOM; Osteoporosis; RANK; RANKL

Indexed keywords

ALENDRONIC ACID; ANASTROZOLE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CALCIUM; DENOSUMAB; EXEMESTANE; LETROZOLE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PLACEBO; VITAMIN D;

ADENOCARCINOMA; ANDROGEN DEPRIVATION THERAPY; ANTIBODY PRODUCTION; APPENDICITIS; ARTHRALGIA; BACKACHE; BONE DENSITY; BONE MASS; BRAIN CANCER; BREAST CANCER; BREAST CARCINOMA; BREAST SURGERY; CANCER RADIOTHERAPY; CELLULITIS; CEREBROVASCULAR ACCIDENT; COLON CANCER; DIVERTICULITIS; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG PREFERENCE; DRUG SAFETY; DRUG SPECIFICITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECZEMA; ENDOCARDITIS; ERYSIPELAS; FATIGUE; FEMUR SHAFT FRACTURE; FLATULENCE; HIP FRACTURE; HUMAN; HYPERTENSION; HYPOCALCEMIA; INFECTION; INJECTION SITE REACTION; JAW OSTEONECROSIS; LABYRINTHITIS; LIMB PAIN; LOBAR PNEUMONIA; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MYCOSIS FUNGOIDES; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; OVARY CANCER; PATIENT SATISFACTION; PNEUMONIA; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; PYELONEPHRITIS; REVIEW; RHINOPHARYNGITIS; SEPSIS; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SORE THROAT; STAPHYLOCOCCAL BACTEREMIA; STOMACH CANCER; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; UTERUS CANCER; VERTEBRA FRACTURE;

ANTIBODIES, MONOCLONAL; BONE REMODELING; FEMALE; HUMANS; MIDDLE AGED; NUCLEAR EXPORT SIGNALS; OSTEOPOROSIS, POSTMENOPAUSAL; RANK LIGAND;

EID: 82455219374     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2011.07.004     Document Type: Review

References (39)

1. Hofbauer L.C., Schoppet M. Clinical implications of the osteoprotegerin RANKL/RANK system for bone and vascular diseases. JAMA 2004, 292:490-495.
2. Zhao L., Huang J., Guo R., et al. Smurf 1 inhibits MSC proliferation and differentiation into osteoblasts through Jun beta degradation. J Bone Miner Res 2010, 25(6):1246-1256.
3. Turner C.H., Robling A.G., Duncan R.L., et al. Do bone cells behave like a neuronal network?. Calcif Tissue Int 2002, 70:435-442.
4. Compston F.E., Vedi S., Kaptoge S., et al. Bone remodeling rate and remodeling balance are not co-regulated in adulthood: Implications for the use of activation frequency as an index of remodeling rate. J Bone Miner Res 2007, 22:1031-1036.
5. Lacey D.L., Timms E., Tan H.L., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93:165-176.
6. Eghbali-Fatourechi G., Khosla S., Sanyal A., et al. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 2003, 111:1221-1230.
7. Shevde N.K., Bendixen A.C., Dienger K.M. Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. Proc Natl Acad Sci U S A 2000, 97:7829-7834.
8. Hofbauer L.C., Gori F., Riggs B.L., et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells. Endocrinology 1999, 40:4382-4389.
9. Sasaki N., Kusano E., Ando Y., et al. Glucocorticoid decreases circulating osteoprotegerin (OPG). Nephrol Dial Transplant 2001, 16:479-482.
10. Fahrleitner A., Prenner G., Leb G., et al. Serum osteoprotegerin is a major determinant of bone density development and prevalent vertebral fracture status following cardiac transplantation. Bone 2003, 89:180-190.
11. Browner W.S., Lui L.Y., Cummings S.R. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures and mortality in elderly women. J Clin Endocrinol Metab 2001, 86:631-637.
12. Bekker P.J., Holloway D., Nakanishi A., et al. The effect of a single dose of osteoprotegerin in post-menopausal women. J Bone Miner Res 2001, 16:348-360.
13. Kostenuik P.J., Nguyen H.Q., McCabe J., et al. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res 2009, 24:182-195.
14. Kostenuik P.J. Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. Curr Opin Pharmacol 2005, 5:618-625.
15. Bekker P.J., Holloway D.L., Rasmussen A.S., et al. A single-dose placebo-controlled study of AMG-162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004, 19(7):1059-1066.
16. Kong Y.Y., Yoshida H., Sarosi I., et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis. Nature 1999, 397:315-323.
17. Lewiecki E.M., Miller P.D., McClung M.R., et al. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low bone mineral density. J Bone Miner Res 2007, 22:1832-1841.
18. Miller P.D., Bolognese M.A., Lewiecki E.M., et al. Effect of denosumab on bone density and turnover in postmenopausal with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 2008, 43:222-229.
19. Miller P.D., Wagman R.B., Peacock M., et al. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial. J Clin Endocrinol Metab 2011, 96(2):394-402.
20. Bone H.G., Bolognese M.A., Yuen C.K., et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 2008, 93(6):2149-2157.
21. Genant H.K., Engelke K., Hanley D.A., et al. Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density. Bone 2010, 47:131-139.
22. Bone H.G., Bolognese M.A., Yuen C.K., et al. Effects of denosumab therapy and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Bone Miner Res 2009, 24(Suppl 1). presentation 1243.
23. Cummings S.R., Martin J.S., McClung M.R., et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009, 361:756-765.
24. Reid I.R., Miller P.D., Brown J.P., et al. Effects of denosumab on bone histomorphometry: The FREEDOM and STAND studies. J Bone Miner Res 2010, 25(10):2256-2265.
25. Chupurlat R, Papapoulos S, Bone HG, et al. Long-term denosumab treatment of postmenopausal women with osteoporosis: results from the first two years of the FREEDOM extension study. American College of Rheumatology Annual Meeting. November 7-11, Atlanta, 2011. p. S903.
26. Kendler D.L., Roux C., Benhamou C.L., et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 2010, 25:72-81.
27. Brown J.P., Prince R.L., Deal C., et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 2009, 24(1):153-161.
28. Kendler D.L., Bessette L., Hill C.D., et al. Preferences and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass. Osteoporos Int 2010, 21:837-846.
29. Kendler D.L., Kaur P., Siddhanti S. Open-label, crossover study evaluating the adherence, preference and satisfaction of denosumab and alendronate treatment in postmenopausal women: results of the second year of the study. J Clin Densitom 2011, 14:158.
30. Smith M.R., Egerdie B., Toriz N.H., et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009, 361:745-755.
31. Smith M.R., Saad F., Egerdie B., et al. Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. J Urol 2009, 182:2670-2672.
32. Ellis G.K., Bone H.G., Chlebowski R., et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 2008, 26:4875-4882.
33. Ellis K.E., Bone H.G., Chlebowski R. Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study. Breast Cancer Res Treat 2009, 118:81-87.
34. Prolia (denosumab) prescribing information. 2010.
35. Jamal SA, Ljunggren O, Stehman-Breen C, et al. The effects of denosumab on bone mineral density and vertebral fracture by level of renal function. Annual Meeting of the American Society for Bone and Mineral Research. Toronto, 2010. Presentation 1068.
36. Adami S., Gilchrist N., Lyritis G., et al. Effect of denosumab on fracture healing in postmenopausal women with osteoporosis: results from the FREEDOM trial. ECTS 2010, OP24 [online].
37. Martin T.J. Paracrine regulation of osteoclast formation and activity: milestones in discovery. J Musculoskelet Neuronal Interact 2004, 4:243-253.
38. Walsh M.C., Kim N., Kadono Y., et al. Osteoimmunology: interplay between the immune system and bone metabolism. Annu Rev Immunol 2006, 24:33-63.
39. Stolina M., Dwyer D., Ominsky M.S., et al. Rats overexpressing soluble osteoprotegerin from a prenatal stage have high bone mass but no alterations in the development of lymphoid organs or innate immune response. J Bone Miner Res 2006, 2:S153.